Skip to main content

Table 4 Comparison between normal and mutant IDH2R140Q patients

From: Prognostic implications of IDH1rs11554137 and IDH2R140Q SNPs mutations in cytogenetically normal acute myeloid leukemia

   Normal IDH2R140Q
(N = 67, 83.7%)
Heterozygous IDH2R140Q mutation
(N = 13, 16.3%)
p value*#
Age (years) Mean ± SD 42.6 ± 16.0 57.2 ± 8.5 0.002
Gender N (%)    0.950
 Male   47 (70.1) 9 (69.3)  
 Female   20 (29.9) 4 (30.7)  
Hepatomegaly N (%)    0.221
 Negative   34 (50.7) 9 (69.3)  
 Positive   33 (49.3) 4 (30.7)  
Splenomegaly N (%)    0.149
 Negative   22 (32.8) 7 (53.8)  
 Positive   45 (67.2) 6 (46.2)  
Lymphadenopathy N (%)    0.037
 Negative   42 (62.7) 12 (92.3)  
 Positive   25 (37.3) 1 (7.7)  
Hemoglobin (g/dl) Mean ± SD 6.7 ± 1.5 7.3 ± 2.2 0.228
TLC (× 109/L) Mean ± SD 77.9.4 ± 39.1 22.2 ± 15.6 < 0.001
Platelets (× 109/L) Mean ± SD 25.9 ± 13.2 49.1 ± 22.7 < 0.001
Blast cells (%) Mean ± SD 70.4 ± 21.0 81.3 ± 7.4 0.069
FAB classification N (%)    0.439
 M1   11 (16.4) 0 (0)  
 M2   35 (52.2) 9 (69.2)  
 M4   16 (23.8) 3 (23.1)  
 M5   5 (7.6) 1 (7.7)  
IDH1SNPrs11554137 N (%)    0.488
 Normal   57 (85.1) 12 (92.3)  
 Heterozygous   10 (14.9) 1 (7.7)  
Outcome at 28 days N (%)    0.010
 Favorable+   18 (26.9) 0 (0)  
 Unfavorable++   49 (73.1) 13 (100)  
Outcome at 6 months N (%)    0.146
 Favorable+   30 (44.8) 3 (23.1)  
 Unfavorable+++   37 (55.2) 10 (76.9)  
Median survival (days) Median (IQR) 160 (25–170) 14 (9–55) 0.027
  1. N number, SD standard deviation, TLC total leucocytic count, IQR interquartile range
  2. *Unpaired t test for quantitative data with parametric distribution
  3. #Chi-square test for qualitative data
  4. Fisher’s exact test when the expected count in any cell was found at less than 5
  5. +Favorable outcome = CR (complete remission)
  6. ++Unfavorable outcome = D (dead) or PR (partial remission)
  7. +++Unfavorable outcome = D (dead) or R (relapsed)
  8. A p value <0.05 was considered the cut-off value for significance in all analyses